Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
Status:
Completed
Trial end date:
2021-04-09
Target enrollment:
Participant gender:
Summary
The PRIME trial will assess the safety of 2 mg intravitreal aflibercept injections (IAI) to
achieve and maintain DRSS improvements (2 or more steps) in patients with a baseline DRSS
level of 47A to 71A inclusive through 104 weeks as determined by reading center determined
DRSS gradings on OPTOS fundus photos and leakage index on OPTOS WF-FA.